AAAAAA
Results: 1-25/34
Authors:
Flamen, P
Hoekstra, OS
Homans, F
Van Cutsem, E
Maes, A
Stroobants, S
Peeters, M
Penninckx, F
Filez, L
Bleichrodt, RP
Mortelmans, L
Citation: P. Flamen et al., Unexplained rising carcinoembryonic antigen (CEA) in the postoperative surveillance of colorectal cancer: the utility of positron emission tomography(PET), EUR J CANC, 37(7), 2001, pp. 862-869
Authors:
Van Cutsem, E
Dicato, M
Wils, J
Citation: E. Van Cutsem et al., Recent advances in the management of colorectal cancer, EUR J CANC, 37(18), 2001, pp. 2302-2309
Authors:
Topal, B
Flamen, P
Aerts, R
D'Hoore, A
Filez, L
Van Cutsem, E
Mortelmans, L
Penninckx, F
Citation: B. Topal et al., Clinical value of whole-body positron emission tomography in potentially curable colorectal liver metastases, EUR J SUR O, 27(2), 2001, pp. 175-179
Authors:
Van Cutsem, E
Twelves, C
Cassidy, J
Allman, D
Bajetta, E
Boyer, M
Bugat, R
Findlay, M
Frings, S
Jahn, M
McKendrick, J
Osterwalder, B
Perez-Manga, G
Rosso, R
Rougier, P
Schmiegel, WH
Seitz, JF
Thompson, P
Vieitez, JM
Weitzel, C
Harper, P
Citation: E. Van Cutsem et al., Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer: Results of a large phase III study, J CL ONCOL, 19(21), 2001, pp. 4097-4106
Authors:
Rothenberg, ML
Meropol, NJ
Poplin, EA
Van Cutsem, E
Wadler, S
Citation: Ml. Rothenberg et al., Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: Summary findings of an independent panel, J CL ONCOL, 19(18), 2001, pp. 3801-3807
Authors:
Van Cutsem, E
Douillard, JY
Kohne, C
Citation: E. Van Cutsem et al., Toxicity of irinotecan in patients with colorectal cancer., N ENG J MED, 345(18), 2001, pp. 1351-1352
Authors:
Tejpar, S
Li, C
Yu, C
Poon, R
Denys, H
Sciot, R
Van Cutsem, E
Cassiman, JJ
Alman, BA
Citation: S. Tejpar et al., Tcf-3 expression and beta-catenin mediated transcriptional activation in aggressive fibromatosis (desmoid tumour), BR J CANC, 85(1), 2001, pp. 98-101
Authors:
Tejpar, S
Cassiman, JJ
Van Cutsem, E
Citation: S. Tejpar et al., The molecular basis of colorectal cancer, ACT GASTR B, 64(3), 2001, pp. 249-254
Authors:
Sobrero, A
Kerr, D
Glimelius, B
Van Cutsem, E
Milano, G
Pritchard, DM
Rougier, P
Aapro, M
Citation: A. Sobrero et al., New directions in the treatment of colorectal cancer: a look to the future, EUR J CANC, 36(5), 2000, pp. 559-566
Authors:
Van Cutsem, E
Haustermans, K
Van Steenbergen, W
Citation: E. Van Cutsem et al., New treatment possibilities for pancreatic and biliary tumours, ANN ONCOL, 11, 2000, pp. 165-169
Authors:
Van Cutsem, E
Findlay, M
Osterwalder, B
Kocha, W
Dalley, D
Pazdur, R
Cassidy, J
Dirix, L
Twelves, C
Allman, D
Seitz, JF
Scholmerich, J
Burger, HU
Verweij, J
Citation: E. Van Cutsem et al., Capecitabine, an oral fluoropyrimidine carbamate with substantial activityin advanced colorectal cancer: Results of a randomized phase II study, J CL ONCOL, 18(6), 2000, pp. 1337-1345
Authors:
Wilke, H
Vanhoefer, U
Rougier, P
Van Cutsem, E
Wils, JA
Baron, B
Citation: H. Wilke et al., Standard chemotherapy for gastric carcinoma: Is it a myth? In reply, J CL ONCOL, 18(23), 2000, pp. 4002-4003
Authors:
Flamen, P
Lerut, A
Van Cutsem, E
De Wever, W
Peeters, M
Stroobants, S
Dupont, P
Bormans, G
Hiele, M
De Leyn, P
Van Raemdonck, D
Coosemans, W
Ectors, N
Haustermans, K
Mortelmans, L
Citation: P. Flamen et al., Utility of positron emission tomography for the staging of patients with potentially operable esophageal carcinoma, J CL ONCOL, 18(18), 2000, pp. 3202-3210
Authors:
Vanhoefer, U
Rougier, P
Wilke, H
Ducreux, MP
Lacave, AJ
Van Cutsem, E
Planker, M
Dos Santos, JG
Piedbois, P
Paillot, B
Bodenstein, H
Schmoll, HJ
Bleiberg, H
Nordlinger, B
Couvreur, ML
Baron, B
Wils, JA
Citation: U. Vanhoefer et al., Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the European organization for research and treatment of cancer gastrointestinal tract cancer cooperative group, J CL ONCOL, 18(14), 2000, pp. 2648-2657
Authors:
Dicato, M
Van Cutsem, E
Wils, J
Citation: M. Dicato et al., Perspectives in colorectal cancer - Introduction, SEMIN ONCOL, 27(5), 2000, pp. 1-1
Authors:
Flamen, P
Van Cutsem, E
Mortelmans, L
Citation: P. Flamen et al., A new imaging technique for colorectal cancer: Positron emission tomography, SEMIN ONCOL, 27(5), 2000, pp. 22-29
Authors:
Van Cutsem, E
Peeters, M
Citation: E. Van Cutsem et M. Peeters, Oral fluoropyrimidines in colorectal cancer, SEMIN ONCOL, 27(5), 2000, pp. 91-95
Authors:
Lerut, T
Flamen, P
Ectors, N
Van Cutsem, E
Peeters, M
Hiele, M
De Wever, W
Coosemans, W
Decker, G
De Leyn, P
Deneffe, G
Van Raemdonck, D
Mortelmans, L
Citation: T. Lerut et al., Histopathologic validation of lymph node staging with FDG-PET scan in cancer of the esophagus and gastroesophageal junction - A prospective study based on primary surgery with extensive lymphadenectomy, ANN SURG, 232(6), 2000, pp. 743-751
Authors:
Van Laethem, JL
Baert, F
Buset, M
de Hemptine, B
De Ronde, T
Honore, P
Lerut, T
Scaillet, P
Van Cutsem, E
Citation: Jl. Van Laethem et al., Curative management of adenocarcinoma of the oesophagus and oesogastric junction - Current recommendations of the Belgian Working Group, ACT GASTR B, 63(3), 2000, pp. 304-306
Authors:
Iveson, TJ
Hickish, T
Schmitt, C
Van Cutsem, E
Citation: Tj. Iveson et al., Irinotecan in second-line treatment of metastatic colorectal cancer: Improved survival and cost-effect compared with infusional 5-FU, EUR J CANC, 35(13), 1999, pp. 1796-1804
Authors:
Van Cutsem, E
Cunningham, D
Huinink, WWT
Punt, CJA
Alexopoulos, CG
Dirix, L
Symann, M
Blijham, GH
Cholet, P
Fillet, G
Van Groeningen, C
Vannetzel, JM
Levi, F
Panagos, G
Unger, C
Wils, J
Cote, C
Blanc, C
Herait, P
Bleiberg, H
Citation: E. Van Cutsem et al., Clinical activity and benefit of irinotecan (CPT-11) in patients with colorectal cancer truly resistant to 5-fluorouracil (5-FU), EUR J CANC, 35(1), 1999, pp. 54-59
Authors:
Van Cutsem, E
Citation: E. Van Cutsem, Raltitrexed (Tomudex (TM)) in combination treatment for colorectal cancer:New perspectives, EUR J CANC, 35, 1999, pp. S1-S2
Authors:
Schmitt, C
Blijham, G
Jolain, B
Rougier, P
Van Cutsem, E
Citation: C. Schmitt et al., Medical care consumption in a phase III trial comparing irinotecan with infusional 5-fluorouracil (5-FU) in patients with metastatic colorectal cancer: after 5-FU failure, ANTI-CANC D, 10(6), 1999, pp. 617-623
Authors:
Tejpar, S
Nollet, F
Li, C
Wunder, JS
Michils, G
dal Cin, P
Van Cutsem, E
Bapat, B
van Roy, F
Cassiman, JJ
Alman, BA
Citation: S. Tejpar et al., Predominance of beta-catenin mutations and beta-catenin dysregulation in sporadic aggressive fibromatosis (desmoid tumor), ONCOGENE, 18(47), 1999, pp. 6615-6620
Authors:
Stockx, L
Raat, H
Caerts, B
Van Cutsem, E
Wilms, G
Marchal, G
Citation: L. Stockx et al., Transcatheter embolization of hepatic arteriovenous fistulas in Rendu-Osler-Weber disease: a case report and review of the literature, EUR RADIOL, 9(7), 1999, pp. 1434-1437